Oxalic Acid

Oxalic Acid

SCHEMBL4114541

FC(F)(F)c1ccc(C2CCN(CCC3CCCc4sccc43)CC2)cc1.O=C(O)C(=O)O

nearest known ligand 0.47

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

OPRM1SLC6A4

The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 1/20 0.43
CYP19A1 P11511 1/20 0.42
TBXAS1 P24557 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
CHRM2 P08172 1/20 0.41
CHRM5 P08912 1/20 0.41
CHRM1 P11229 1/20 0.41
CHRM3 P20309 1/20 0.41
P2RY14 Q15391 1/20 0.40
HTR2C P28335 1/20 0.39
LHCGR P22888 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4101634 0.94 CYP19A1 (0.47) SIGMAR1CYP19A1TBXAS1L3MBTL1
Oxalic Acid SCHEMBL4107668 0.93 SIGMAR1 (0.43) SIGMAR1CYP19A1TBXAS1HTR2C
Oxalic Acid SCHEMBL4102628 0.89 HTR2C (0.49) SIGMAR1CYP19A1TBXAS1HTR2C
Oxalic Acid SCHEMBL4108518 0.88 SIGMAR1 (0.55) SIGMAR1CYP19A1TBXAS1
Oxalic Acid SCHEMBL4107494 0.87 DRD2 (0.45) SIGMAR1CYP19A1TBXAS1LHCGR
Oxalic Acid SCHEMBL4108924 0.87 SIGMAR1 (0.48) SIGMAR1CYP19A1TBXAS1HTR2C
SCHEMBL4111011 0.87 CYP19A1 (0.46) SIGMAR1CYP19A1TBXAS1L3MBTL1
Oxalic Acid SCHEMBL4103987 0.85 DRD2 (0.48) SIGMAR1CYP19A1TBXAS1LHCGR
SCHEMBL4106870 0.82 CYP19A1 (0.49) SIGMAR1CYP19A1TBXAS1HTR2C
SCHEMBL4098226 0.82 SIGMAR1 (0.60) SIGMAR1CYP19A1TBXAS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8492563-B2 4,5,6,7-tetrahydrobenzo[B]thiophene derivatives and their use as sigma receptor ligands LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2013-07-23 US claimed
US-20120238567-A1 4,5,6,7-TETRAHYDROBENZO[B]THIOPHENE DERIVATIVES AND THEIR USE AS SIGMA RECEPTOR LIGANDS LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2012-09-20 US claimed
US-8227625-B2 4,5,6,7-tetrahydrobenzo[b]thiophene derivatives and their use as sigma receptor ligands LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2012-07-24 US claimed
US-20090221572-A1 4,5,6,7-TETRAHYDROBENZO[B]THIOPHENE DERIVATIVES AND THEIR USE AS SIGMA RECEPTOR LIGANDS LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2009-09-03 US claimed
EP-1996573-A1 4, 5, 6,7-TETRAHYDROBENZO[B]THIOPHENE DERIVATIVES AND THEIR USE AS SIGMA RECEPTOR LIGANDS Laboratorios del Dr. Esteve S.A. (ES) 2008-12-03 EP claimed
WO-2007098961-A1 4, 5, 6,7-TETRAHYDROBENZO[B]THIOPHENE DERIVATIVES AND THEIR USE AS SIGMA RECEPTOR LIGANDS LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2007-09-07 WO claimed
US-8492563-B2 4,5,6,7-tetrahydrobenzo[B]thiophene derivatives and their use as sigma receptor ligands LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2013-07-23 US disclosed
US-20120238567-A1 4,5,6,7-TETRAHYDROBENZO[B]THIOPHENE DERIVATIVES AND THEIR USE AS SIGMA RECEPTOR LIGANDS LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2012-09-20 US disclosed
US-8227625-B2 4,5,6,7-tetrahydrobenzo[b]thiophene derivatives and their use as sigma receptor ligands LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2012-07-24 US disclosed
US-20090221572-A1 4,5,6,7-TETRAHYDROBENZO[B]THIOPHENE DERIVATIVES AND THEIR USE AS SIGMA RECEPTOR LIGANDS LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2009-09-03 US disclosed
EP-1996573-A1 4, 5, 6,7-TETRAHYDROBENZO[B]THIOPHENE DERIVATIVES AND THEIR USE AS SIGMA RECEPTOR LIGANDS Laboratorios del Dr. Esteve S.A. (ES) 2008-12-03 EP disclosed
WO-2007098961-A1 4, 5, 6,7-TETRAHYDROBENZO[B]THIOPHENE DERIVATIVES AND THEIR USE AS SIGMA RECEPTOR LIGANDS LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2007-09-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221572-A1 4,5,6,7-TETRAHYDROBENZO[B]THIOPHENE DERIVATIVES AND THEIR USE AS SIGMA RECEPTOR LIGANDS SIGMAR1, TMEM97, OPRM1 SIGMAR1 1/4885CYP19A1 1958/4885TBXAS1 1186/4885
US-20120238567-A1 4,5,6,7-TETRAHYDROBENZO[B]THIOPHENE DERIVATIVES AND THEIR USE AS SIGMA RECEPTOR LIGANDS SIGMAR1, TMEM97, OPRM1 SIGMAR1 1/4885CYP19A1 1958/4885TBXAS1 1186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.